The parasiticide category is being transformed by long-acting platforms. Boehringer Ingelheim's NEXGARD reached $1.5 billion in 2025 sales (+8.5%), holding the industry's top-selling parasiticide position. Zoetis's Simparica Trio surpassed $1 billion in U.S. sales in 2025. In July 2025 Merck Animal Health gained FDA approval for BRAVECTO QUANTUM, the first-ever once-yearly injectable parasiticide for dogs — fundamentally shifting the duration paradigm from monthly to annual dosing. Compliance gains alone are forecast to expand the addressable market by 25-30%. Generic entrants including Norbrook and Bimeda are accelerating pricing pressure on off-patent molecules.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Parasiticide Market Size, Growth and Forecast 2025-2030 by Duration and Route
• Once-Yearly Injectables — BRAVECTO QUANTUM and Pipeline Candidates
• Multi-Month Oral Parasiticides — NEXGARD, Simparica, Bravecto Chews
• Combination Parasiticides — Simparica Trio, NEXGARD COMBO, Triple-Action
• Topical Long-Acting Parasiticides — Seresto, Frontline Shield
• Heartworm Prevention — Long-Acting Injectables, Annual Protection Platforms
• Livestock Parasiticides — Cattle Pour-Ons, Sheep and Goat Treatments
• Resistance Management — Rotation Strategies and Novel Mechanisms of Action
• Veterinary Channel Dynamics — Compliance Gains, In-Clinic vs. Retail Shift
• Regulatory Landscape — FDA CVM, EMA, and Generic Entry Risk
• Competitive Landscape — Top 10 Pipelines and Generic Entrants
• Market Challenges and Risks — Generic Entry, Pricing Pressure, Resistance
Table of Contents
1. Executive Summary
2. Market Overview
3. Parasiticide Market Size, Growth and Forecast 2025-2030
4. Once-Yearly Injectables
5. Multi-Month Oral Parasiticides
6. Combination Parasiticides
7. Topical Long-Acting Parasiticides
8. Heartworm Prevention
9. Livestock Parasiticides
10. Resistance Management
11. Regulatory Landscape
12. Regional Analysis
13. Market Challenges and Risks
14. Competitive Landscape
15. Strategic Conclusions and Recommendations
16. Appendix
List of Tables
Table 1. Parasiticide Market Size and Forecast 2025-2030 by Duration and Route
Table 2. Top 20 Companion Animal Parasiticide Brands by Revenue 2025
Table 3. NEXGARD, Simparica, BRAVECTO Sales 2023-2025
Table 4. Once-Yearly Injectable Pipeline by Supplier 2025
Table 5. Combination Parasiticide Pipeline — Triple Action Programs
Table 6. Heartworm Prevention Market Size and Forecast 2025-2030
Table 7. Livestock Parasiticide Sales by Species and Region 2025
Table 8. Generic Entry Timeline and Patent Cliff Analysis 2025-2030
Table 9. Veterinary Channel vs. Retail Channel Sales Mix 2023-2025
Table 10. Competitive Positioning by Duration Class
Companies Profiled
Bimeda
Boehringer Ingelheim Animal Health
Ceva Santé Animale
Dechra Pharmaceuticals
Elanco Animal Health
Merck Animal Health
Norbrook Laboratories
PetIQ
Vetoquinol
Virbac
Zoetis
